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Purified recombinant VIM-7 possesses efficient penicillinase and carbapenemase activities comparable to
those of VIM-2. Cephalosporinase activity was variable and generally lower than those of VIM-1 and VIM-2.
A homology model suggests that the VIM-7 Tyr-218 Phe substitution may be responsible for the reduced
catalytic efficiency against certain cephalosporins, including ceftazidime and cefepime.
Metallo--lactamases (MBLs) effectively hydrolyze most
-lactams and are not inhibited by clinical -lactamase inhib-
itors (13, 16). Five clinically important MBLs (IMP, VIM,
SPM, GIM, and SIM) are reported to be encoded by genes
located on plasmids or associated with mobile genetic elements
(13, 16). So far, 18 distinct VIM enzymes from a variety of
gram-negative opportunist pathogens have been described
(www.lahey.org/Studies). We have previously identified
VIM-7, the most divergent of all reported VIM subtypes (77%
amino acid identity with VIM-1) and the first MBL to be
reported from the United States (14). Here we report the
overexpression of VIM-7 in Escherichia coli and the kinetic
characterization of the purified enzyme.
The blaVIM-7 gene was amplified from Pseudomonas aerugi-
nosa 07-406 (14) by PCR using the primers VIM-7F 5-GAAT
TCCATATGTTTCAAATTCGCAGCTTTCTGGTTG-3 and
VIM-7R 5-CGCGGATCCTTACTCGGCCACCGGGCGTAC
TTTG-3 to introduce NdeI and BamHI restriction sites, respec-
tively (underlined). The PCR product was cloned into the T7
expression vector pET-26b (Novagen) and transformed into E.
coli BL21 (DE3) (Novagen). Protein expression was induced in
Terrific broth (Sigma-Aldrich) at 37°C by using 1 mM isopro-
pyl-1-thio--D-galactopyranoside.VIM-7 was purified from the
periplasm according to the method of Avison et al. (1) with
modifications including 50 mM Tris (pH 7.5), 100 M ZnCl2,
0.02% (wt/vol) sodium azide used as the buffer system, and
Q-Sepharose and Superdex 75 matrices (GE Healthcare) for
the ion-exchange and gel filtration steps, respectively. In addi-
tion, blaVIM-2 was amplified from P. aeruginosa 81-11963 (15)
by using primers VIM-2F 5-GGAATTCCATATGTTCAAACT
TTTGAGTAAGTTATTGG and VIM-2R 5-CGCGGATCCC
TACTCAACGACTGAGCGATTTGTG (NdeI and BamHI re-
striction sites underlined), and cloned, expressed and purified as
described for VIM-7. The concentrations of VIM-7 and VIM-2
were determined from the absorbance at 280 nm by using extinc-
tion coefficients of 26,930 M1 cm1 (calculated from the amino
acid sequence [www.expasy.ch]) and 28,500 M1 cm1 (2), re-
spectively. Protein preparations were estimated to be99% pure,
as judged by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis.
Steady-state kinetic measurements were performed at 25°C
in UV-transparent 96-well plates (BD Biosciences) in a Spec-
traMax 190 spectrophotometer (Molecular Devices) in 50 mM
sodium cacodylate (pH 7.0), 100 M ZnCl2, and 0.1 mg/ml
bovine serum albumin. A parallel investigation of nitrocefin
hydrolysis by VIM-7 in 1-ml cuvettes yielded kinetic parame-
ters identical to those obtained with 96-well plates (data not
shown). The wavelengths and extinction coefficients used were
those previously reported (7, 12) excepting those for ertap-
enem (ε, 6,920 M1 cm1; , 300 nm). For 96-well plates,
extinction coefficients were recalculated from standard curves
constructed from absorbance measurements of serially diluted
unhydrolyzed and completely hydrolyzed substrates. Km (M)
and kcat (s
1) were determined from plots of initial velocity of
hydrolysis against substrate concentration. For penicillin G,
ampicillin, carbenicillin, piperacillin, aztreonam, and clavu-
lanic acid, the Km was determined as the Ki by measuring
inhibition of hydrolysis of the reporter substrate nitrocefin
across a range of substrate and nitrocefin concentrations. Ki val-
ues were determined by a global (shared-parameter) fit of these
multiple data sets to a competitive inhibition model. All kinetic
data were fitted by nonlinear regression as implemented in the
Prism program (GraphPad Software, San Diego, CA).
Table 1 lists the steady-state kinetic parameters kcat, Km,
* Corresponding author. Mailing address for Ørjan Samuelsen: Ref-
erence Centre for Detection of Antimicrobial Resistance, Department
of Microbiology and Infection Control, University Hospital of North
Norway, 9038 Tromsø, Norway. Phone: (47) 776 27043. Fax: (47) 776
27015. E-mail: orjan.samuelsen@unn.no. Mailing address for James
Spencer: Department of Cellular and Molecular Medicine, University
of Bristol, School of Medical Sciences, University Walk, Bristol BS8
1TD, United Kingdom. Phone: (44) (0) 117 331 2084. Fax: (44) (0) 117
331 2091. E-mail: Jim.Spencer@bristol.ac.uk.
 Published ahead of print on 16 June 2008.
2905
 o
n
 February 24, 2014 by Cardiff Univ
http://aac.asm
.org/
D
ow
nloaded from
 
and kcat/Km for hydrolysis of a series of substrates by VIM-7
and compares these data with published values for VIM-1 and
VIM-2 (2, 3) and data from our own investigations of cloxacil-
lin, ertapenem, and clavulanic acid hydrolysis by VIM-2 (this
study). Note that we also investigated hydrolysis of nitrocefin
and cephaloridine by VIM-2 under our conditions and found
no major discrepancies with previously published values (2).
VIM-7 hydrolyzed all the tested -lactams except aztreonam,
for which only very weak interaction with enzyme was ob-
served. VIM-7 efficiently hydrolyzes all penicillins and carbap-
enems (kcat/Km  10
6 M1 s1) with the exception of ertap-
enem, while activity against cephalosporins varies by almost
four orders of magnitude (activity against cefepime, 9.1 	 103
M1 s1; activity against nitrocefin, 2.6 	 107 M1 s1). The
-lactamase inhibitors tazobactam, sulbactam, and clavulanic
acid are hydrolyzed with lower efficiencies, due primarily to
high Km values. Activity against penicillins, and to some extent
carbapenems, arises both from high kcat and, with the excep-
tion of that for cloxacillin, relatively tight (10 to 100 M) Km
values. Comparison with VIM-1 and VIM-2 (Table 1) suggests
three general trends in overall catalytic efficiency. That for
penicillins is VIM-7  VIM-2  VIM-1, that for cephalospo-
rins is VIM-1 
 VIM-2  VIM-7, and that for carbapenems is
VIM-7 
 VIM-2  VIM-1. The trend in kcat/Km values for
VIM-7 broadly follows that observed for MICs determined
with E. coli DH5 transformed with the pMATVIM-7 plasmid
(14) in that penicillin MICs are generally high, the value for
imipenem is higher than that for meropenem, and there is little
effect on aztreonam susceptibility.
Experiments in which VIM-7 (2 nM) was incubated with
EDTA (200 M) at set time points and activity assessed by
nitrocefin (100 M) hydrolysis rates revealed loss of more than
85% of activity in an incubation period of 2 h. The inactivation
process was dominated by an exponential process with a rate
(0.014 min1) comparable to the slower of the two phases
(0.012 min1) observed in the equivalent experiment per-
formed with P. aeruginosa SPM-1 (9). However, the data also
suggest a second, faster phase (0.48 min1) accounting for
approximately one-eighth of the activity lost. Although this
might be considered indicative of the presence of two metal
sites of significantly differing affinities, as has been proposed
for SPM-1 (8), further experiments are necessary to resolve
this point.
A homology model of VIM-7 (Fig. 1) constructed using the
EsyPred3D server (www.fundp.ac.be/urbm/bioinfo/esypred)
(6) based on the structure of reduced VIM-2 (5) suggests that
four residues (positions 68, 218, 224, and 228) might have an
impact upon substrate binding and hydrolysis. The Pro-68 Ser
and Tyr-218 Phe substitutions are unique to VIM-7, while
VIM-7 shares the Tyr-224 His substitution with VIM-1,
TABLE 1. Steady-state kinetic parameters of the purified VIM-7 in comparison with those of the other variants, VIM-1 and VIM-2a
Substrate
Km (M) kcat (s1) kcat/Km (M1  s1)
VIM-7 VIM-1b VIM-2b VIM-7 VIM-1b VIM-2b VIM-7 VIM-1b VIM-2b
Penicillins
Benzylpenicillin 17  2c 840 70 430  2 30 280 25 0.036 4
Ampicillin 15  2c 920 90 190  17 35 125 13 0.038 1.4
Carbenicillin 84  10c 75 205 1,200  74 170 185 14 2.3 0.9
Piperacillin 26  3c 3,500 125 140  13 1,900 300 5.4 0.54 2.4
Azlocillin 66  16 120 200 78  4 1,500 200 1.2 12.5 1.0
Cloxacillin 860  310 ND 250  47 2,500  400 ND 350  18 2.9 ND 1.4
Cephalosporins
Cephalothin 45  5 55 11 180  6 280 130 4.0 5.1 12
Cephaloridine 250  21 30 50 180  6 315 140 0.72 10.5 2.8
Cefoxitin 68  7 130 13 10  0.3 26 15 0.15 0.2 1.2
Cefuroxime 29  4 42 20 16  0.5 325 8 0.55 7.7 0.4
Cefotaxime 22  2 250 12 56  2 170 70 2.6 0.68 5.8
Ceftazidime 120  25 800 72 1.4  0.1 60 3.6 0.012 0.075 0.05
Cefepime 580  61 150 400 5.3  0.2 550 40 0.0091 3.7 0.1
Nitrocefin 58  3 17 18 1,500  29 95 770 26 5.6 42.8
Moxalactam 75  15 450 55 230  13 43 90 3.1 0.096 1.6
Carbapenems
Imipenem 27  2 1.5 9 100  2 0.2 34 3.7 0.13 3.8
Meropenem 38  4 50 2 42  0.8 13 5 1.1 0.26 2.5
Ertapenem 28  3 ND 9  0.6 8  0.2 ND 0.2  0.01 0.29 ND 0.022
Monobactam (aztreonam) 2,700  630c 1,000 1,000 NH 0.01 0.01 ND 1.0 	 102 1.0 	 102
Inhibitors
Tazobactam 3,500  360 340 875 68  3 5.3 28 0.019 0.016 0.032
Sulbactam 740  90 200 320 110  6 10 23 0.15 0.05 0.072
Clavulanic acid 940  320c ND 5,000c 2.3  0.4d ND 5.4  2.1d 0.0025 ND 0.0011
a ND, data not determined; NH, no measurable hydrolysis.
b Kinetic constants for VIM-1 are from Franceschini et al. (3), and those for VIM-2 are from Docquier et al. (2) except for those for cloxacillin, ertapenem, and
clavulanic acid (this study).
c Km values were measured as inhibition constants (Ki) in a competitive model using nitrocefin as the reporter substrate.
d kcat values were calculated from fits of initial velocity against the clavulanate concentration assuming the Km equals the Ki (from the experiment).
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VIM-4, and VIM-12 only. Arg-228 is present in all VIM en-
zymes other than VIM-1 and VIM-12. Pro-68, a well-conserved
residue in subclass B1 MBLs, forms an H bond to the Zn2
ligand His-263 through its main-chain carbonyl oxygen, and
although the replacement of this residue by Ser will likely
increase flexibility in this region of the protein, our model does
not suggest that this interaction will be abolished. VIM-2 Tyr-
218 participates in an H-bonding network, involving Asp-84,
that is present in some form in all MBLs of known structure
and connects the two Zn2 sites (8). In the related IMP en-
zymes, enhancing these interactions through the Phe-218 Tyr
mutation promotes hydrolysis of so-called type II -lactam
substrates with neutral or charged substituents at the C-2/C-3
(R2) position (10, 11). Our model suggests that in VIM-7,
replacement of Tyr-218 by Phe will disrupt this network
(Fig. 1). Consistent with this hypothesis, VIM-7 indeed dis-
plays a loss of activity against type II cephalosporins bearing
charged cyclic substituents (ceftazidime, cefepime, and
cephaloridine).
For VIM-2 (2), the Tyr-224 hydroxyl is suggested to interact
with the charged C-2/C-3 (R2) substituents of some -lactams,
while Arg-228 is proposed to make effective H bonds to the
invariant -lactam C-3/C-4 carboxylate. The generally tight Km
values observed with VIM-7 (Arg-228), compared with those
reported for VIM-1 (Ser-228), would support the latter con-
clusion. The structure suggests that the Tyr-224 hydroxyl moi-
ety makes a second-shell metal-ligand interaction by H bond-
ing via a water molecule (Wat-X) (Fig. 1) to the distal nitrogen
of the Zn1 ligand His-196. Substitution of Tyr-224 for His
might be expected to disrupt this interaction. Nevertheless, the
efficient hydrolysis of many substrates by VIM-7 suggests ei-
ther that this interaction is of marginal importance to the
function of the VIM active site or that compensating structural
rearrangements are possible.
In summary, our kinetic data show that, despite possessing a
number of alterations close to the active site, VIM-7 effectively
hydrolyzes both penicillin and carbapenem substrates but dis-
plays some diminished activity against cephalosporins, partic-
ularly those with bulky, charged C-3 substituents. Analysis of a
VIM-7 homology model suggests that these effects might arise
primarily from the Tyr-218 Phe substitution that distinguishes
this enzyme from other family members. Further structural
and mutagenic studies will be required to confirm this hypoth-
esis.
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